ArticleBreast cancer research : BCR2021
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry.
Article in Breast cancer research : BCR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 4 syntheses or guidelines pooled it, 150 citations in OpenAlex.
- Survival disparities in HER2-low versus HER2-positive breast cancer: a systematic review of progression-free survival and overall survival.Frontiers in oncology · 2026Pooled it
- 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7).Breast (Edinburgh, Scotland) · 2024Guideline
- HER2-low prevalence among Hispanic/Latino women with breast cancer: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis.ESMO open · 2023Pooled it
- Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2-Low, Hormone Receptor-Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials.JCO precision oncology · 2025Trial
- Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- HER2-low metastatic breast cancers: clinic-pathological characteristics, metastatic sites, and survival impact on biomarker discordance.Virchows Archiv : an international journal of pathology · 2026Article
- Comparison of Stromal Tumor-Infiltrating Lymphocyte (sTIL) Levels and Clinicopathological Features in Neoadjuvant-Naive HER2-Low and HER2-Negative Primary Breast Cancers.Medicina (Kaunas, Lithuania) · 2026Article
- Intratumoral and peritumoral habitat imaging based on multiparametric MRI to predict HER2-negative breast cancer subtypes: a multicenter study.BMC medical imaging · 2026Article
- Real-World Study Assessing Characteristics and Treatment Patterns of Patients With Human Epidermal Growth Factor Receptor 2 Immunohistochemistry 0 and Human Epidermal Growth Factor Receptor 2-Low Stage IV Breast Cancer: A Multicenter Retrospective Study.JCO precision oncology · 2026Article
- Clinical characteristics and prognostic impact of HER2-ultralow breast cancer and tumor-infiltrating lymphocytes (TILs).BMC cancer · 2025Article
- Differences in Sentinel lymph node biopsy outcomes and prognosis between HER2-low and HER2-zero breast cancer.BMC cancer · 2025Article
- Real-world treatment patterns and outcomes of patients with hormone receptor-positive/HER2-low metastatic breast cancer treated with chemotherapy.The oncologist · 2025Article
- Prognostic difference between early breast cancer patients with HER2 low and HER2 zero status.NPJ breast cancer · 2025Article
- Clinicopathological features and prognosis of breast cancer with low HER2 status evaluated by fluorescenceOncology letters · 2025Article
- Advances in research and current challenges in the treatment of advanced HER2-low breast cancer.Frontiers in cell and developmental biology · 2025Review
- Real-world analysis of HER2-ultralow in HR+/HER2- metastatic breast cancer: prevalence and first-line chemotherapy outcomes.Therapeutic advances in medical oncology · 2025Article
- Patient characteristics and treatment patterns of patients with locally advanced or metastatic HER2-low breast cancer, a single site descriptive study.Breast cancer research and treatment · 2024Article
- Molecular Analysis of PIK3CA in Metastatic Hormone Receptor-Positive Breast Cancer in Chile: Clinical and Pathological Insights.International journal of molecular sciences · 2024Article
- A Nationwide Study on HER2-Low Breast Cancer in South Korea: Its Incidence of 2022 Real World Data and the Importance of Immunohistochemical Staining Protocols.Cancer research and treatment · 2024Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 12 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAbout 50% of all primary breast cancers show a low-level expression of HER2 (HER2-low), defined as immunohistochemically 1+ or 2+ and lack of HER2 gene amplification measured by in situ hybridization. This low HER2 expression is a promising new target for antibody-drug conjugates (ADCs) currently under investigation. Until now, little is known about the frequency and the prognostic value of low HER2-expression in metastatic breast cancer (MBC). PATIENTS AND
methodsThe MBC-Registry of the Austrian Study Group of Medical Tumor Therapy (AGMT) is a multicenter nationwide ongoing registry for MBC patients in Austria. Unadjusted, univariate survival probabilities of progression-free survival (PFS) and overall survival (OS) were calculated by the Kaplan-Meier method and compared by the log-rank test. Multivariable adjusted hazard ratios were estimated by Cox regression models. In this analysis, only patients with known HER2 status and available survival data were included.
resultsAs of 11/15/2020, 1,973 patients were included in the AGMT-MBC-Registry. Out of 1,729 evaluable patients, 351 (20.3%) were HER2-positive, 608 (35.2%) were HER2-low and 770 (44.5%) were completely HER2-negative (HER2-0). Low HER2-expression was markedly more frequent in the hormone-receptor(HR)+ subgroup compared to the triple-negative subgroup (40% vs. 23%). In multivariable analysis, low HER2 expression did not significantly influence OS neither in the HR+ (HR 0.89; 95% CI 0.74-1.05; P = 0.171) nor in the triple-negative subgroup (HR 0.92; 95% CI 0.68-1.25; P = 0.585), when compared to completely HER2-negative disease. Similar results were observed when HER2 IHC 2+ patients were compared to IHC 1+ or 0 patients.
conclusionLow-HER2 expression did not have any impact on prognosis of metastatic breast cancer in this real-world population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.